Compounds > l 650719
Page last updated: 2024-11-07

l 650719

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID146921
CHEMBL ID314803
SCHEMBL ID1805957
MeSH IDM0154349

Synonyms (20)

Synonym
CHEMBL314803 ,
l 650719
6-hydroxy-1-benzothiophene-2-sulfonamide
1701w6xc9t ,
benzo(b)thiophene-2-sulfonamide, 6-hydroxy-
unii-1701w6xc9t
6-hts
96803-89-3
l-650719
6-hydroxybenzo(b)thiophene-2-sulfonamide
bdbm50405896
AKOS022656969
XRZYWSVMYHEQPN-UHFFFAOYSA-N
6-hydroxy-2-sulfamoylbenzo[b]thiophene
SCHEMBL1805957
6-hydroxybenzo[b]thiophene-2-sulfonamide
DTXSID50242519
6-hydroxybenzo[b]-thiophene-2-sulfonamide
FT-0743853
STARBLD0001816
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Carbonic anhydrase 2Homo sapiens (human)IC50 (µMol)0.00930.00021.10608.3000AID47732; AID47738
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (12)

Processvia Protein(s)Taxonomy
morphogenesis of an epitheliumCarbonic anhydrase 2Homo sapiens (human)
positive regulation of synaptic transmission, GABAergicCarbonic anhydrase 2Homo sapiens (human)
positive regulation of cellular pH reductionCarbonic anhydrase 2Homo sapiens (human)
angiotensin-activated signaling pathwayCarbonic anhydrase 2Homo sapiens (human)
regulation of monoatomic anion transportCarbonic anhydrase 2Homo sapiens (human)
secretionCarbonic anhydrase 2Homo sapiens (human)
regulation of intracellular pHCarbonic anhydrase 2Homo sapiens (human)
neuron cellular homeostasisCarbonic anhydrase 2Homo sapiens (human)
positive regulation of dipeptide transmembrane transportCarbonic anhydrase 2Homo sapiens (human)
regulation of chloride transportCarbonic anhydrase 2Homo sapiens (human)
carbon dioxide transportCarbonic anhydrase 2Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (5)

Processvia Protein(s)Taxonomy
arylesterase activityCarbonic anhydrase 2Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 2Homo sapiens (human)
protein bindingCarbonic anhydrase 2Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 2Homo sapiens (human)
cyanamide hydratase activityCarbonic anhydrase 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (6)

Processvia Protein(s)Taxonomy
cytoplasmCarbonic anhydrase 2Homo sapiens (human)
cytosolCarbonic anhydrase 2Homo sapiens (human)
plasma membraneCarbonic anhydrase 2Homo sapiens (human)
myelin sheathCarbonic anhydrase 2Homo sapiens (human)
apical part of cellCarbonic anhydrase 2Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 2Homo sapiens (human)
cytoplasmCarbonic anhydrase 2Homo sapiens (human)
plasma membraneCarbonic anhydrase 2Homo sapiens (human)
apical part of cellCarbonic anhydrase 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID165485Reduction in maximum Intra ocular pressure in the rabbit model of ocular hypertension, when treated with a minimum effective oral dose of 0.101989Journal of medicinal chemistry, Dec, Volume: 32, Issue:12
Topically active carbonic anhydrase inhibitors. 2. Benzo[b]thiophenesulfonamide derivatives with ocular hypotensive activity.
AID166661In vivo intraocular pressure reduction was determined in rabbits after effective topical dose (duration expressed as number of time points, P<=0.05)1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Topically active carbonic anhydrase inhibitors. 3. Benzofuran- and indole-2-sulfonamides.
AID47738In vitro inhibition of human carbonic anhydrase II (0.1 nM).1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Topically active carbonic anhydrase inhibitors. 3. Benzofuran- and indole-2-sulfonamides.
AID165488Reduction in maximum Intra ocular pressure in the rabbit model of ocular hypertension, when treated with a minimum effective oral dose of 1.25 mg/kg1989Journal of medicinal chemistry, Dec, Volume: 32, Issue:12
Topically active carbonic anhydrase inhibitors. 2. Benzo[b]thiophenesulfonamide derivatives with ocular hypotensive activity.
AID21555Solubility1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Topically active carbonic anhydrase inhibitors. 3. Benzofuran- and indole-2-sulfonamides.
AID76009Number of animals showing dermal sensitization/ number of animals tested in Magnusson-Kligman assay.1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Topically active carbonic anhydrase inhibitors. 3. Benzofuran- and indole-2-sulfonamides.
AID226457Extent of reaction with 5 equiv of reduced glutathione (GSH) between 16 and 22 hours at pH 7.4 and 37 degree C1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Topically active carbonic anhydrase inhibitors. 3. Benzofuran- and indole-2-sulfonamides.
AID165484Reduction in maximum Intra ocular pressure in the rabbit model of ocular hypertension, when treated with a minimum effective oral dose of 0.051989Journal of medicinal chemistry, Dec, Volume: 32, Issue:12
Topically active carbonic anhydrase inhibitors. 2. Benzo[b]thiophenesulfonamide derivatives with ocular hypotensive activity.
AID226456Extent of reaction with 20 equiv of reduced glutathione (GSH) in 20 hours at pH 7.4 and 37 degree C1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Topically active carbonic anhydrase inhibitors. 3. Benzofuran- and indole-2-sulfonamides.
AID33521Maximum fall in IOP after 50 microL dose of 0.5% concentration in alpha-CT rabbit model.1991Journal of medicinal chemistry, Oct, Volume: 34, Issue:10
Topically active carbonic anhydrase inhibitors. 4. [(Hydroxyalkyl)sulfonyl]benzene and [(hydroxyalkyl)sulfonyl]thiophenesulfonamides.
AID33520Tested in vivo for the IOP (intraocular pressure) recovery after 50 uL dose of 2% concentration in albino rabbits.1991Journal of medicinal chemistry, Oct, Volume: 34, Issue:10
Topically active carbonic anhydrase inhibitors. 4. [(Hydroxyalkyl)sulfonyl]benzene and [(hydroxyalkyl)sulfonyl]thiophenesulfonamides.
AID167127METD(minimum effective topical dose of the compound) for ocular hypotensive activity in alpha-CT-rabbits1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Topically active carbonic anhydrase inhibitors. 3. Benzofuran- and indole-2-sulfonamides.
AID4773250% inhibition of human carbonic anhydrase II assayed by CO2 hydration catalyzed by human erythrocytes1989Journal of medicinal chemistry, Dec, Volume: 32, Issue:12
Topically active carbonic anhydrase inhibitors. 2. Benzo[b]thiophenesulfonamide derivatives with ocular hypotensive activity.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (66.67)18.7374
1990's2 (33.33)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.28

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.28 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.28)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (16.67%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (83.33%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
acetazolamide
Acetazolamide: One of the CARBONIC ANHYDRASE INHIBITORS that is sometimes effective against absence seizures. It is sometimes useful also as an adjunct in the treatment of tonic-clonic, myoclonic, and atonic seizures, particularly in women whose seizures occur or are exacerbated at specific times in the menstrual cycle. However, its usefulness is transient often because of rapid development of tolerance. Its antiepileptic effect may be due to its inhibitory effect on brain carbonic anhydrase, which leads to an increased transneuronal chloride gradient, increased chloride current, and increased inhibition. (From Smith and Reynard, Textbook of Pharmacology, 1991, p337)		1.9710monocarboxylic acid amide;
sulfonamide;
thiadiazoles		anticonvulsant;
diuretic;
EC 4.2.1.1 (carbonic anhydrase) inhibitor
dichlorphenamide
Dichlorphenamide: A carbonic anhydrase inhibitor that is used in the treatment of glaucoma.. diclofenamide : A sulfonamide that is benzene-1,3-disulfonamide in which the hydrogens at positions 4 and 5 are substituted by chlorine. An oral carbonic anhydrase inhibitor, it partially suppresses the secretion (inflow) of aqueous humor in the eye and so reduces intraocular pressure. It is used for the treatment of glaucoma.		1.9710dichlorobenzene;
sulfonamide		antiglaucoma drug;
EC 4.2.1.1 (carbonic anhydrase) inhibitor;
ophthalmology drug
ethoxzolamide
Ethoxzolamide: A carbonic anhydrase inhibitor used as diuretic and in glaucoma. It may cause hypokalemia.. ethoxzolamide : A sulfonamide that is 1,3-benzothiazole-2-sulfonamide which is substituted by an ethoxy group at position 6. A carbonic anhydrase inhibitor, it has been used in the treatment of glaucoma, and as a diuretic.		2.3720aromatic ether;
benzothiazoles;
sulfonamide		antiglaucoma drug;
diuretic;
EC 4.2.1.1 (carbonic anhydrase) inhibitor
methazolamide
Methazolamide: A carbonic anhydrase inhibitor that is used as a diuretic and in the treatment of glaucoma.		1.9710sulfonamide;
thiadiazoles
thiophenes
Thiophenes: A monocyclic heteroarene furan in which the oxygen atom is replaced by a sulfur.. thiophenes : Compounds containing at least one thiophene ring.		4.2741mancude organic heteromonocyclic parent;
monocyclic heteroarene;
thiophenes;
volatile organic compound		non-polar solvent
thiazoles
[no description available]		1.97101,3-thiazoles;
mancude organic heteromonocyclic parent;
monocyclic heteroarene
l 645151
L 645151: structure given in first source		1.9710
hydroxyethylcellulose
hydroxyethylcellulose: component of contact lens wetting solutions; aldiamed is an artificial saliva; RN given refers to parent cpd. hydroxyethylcellulose : A polysaccharide derivative that is cellulose in which hydroxyethyl groups are bound to some of the hydroxyl groups of the glucopyranose monomers.		1.9710
6-hydroxybenzothiazide-2-sulfonamide
6-hydroxybenzothiazide-2-sulfonamide: structure given in first source		1.9710
cellulose
DEAE-Cellulose: Cellulose derivative used in chromatography, as ion-exchange material, and for various industrial applications.		1.9710glycoside
ConditionIndicatedRelationship StrengthStudiesTrials
Glaucoma, Suspect
[description not available]		02.6730
Intraocular Pressure
The pressure of the fluids in the eye.		04.2741
Ocular Hypertension
A condition in which the intraocular pressure is elevated above normal and which may lead to glaucoma.		02.6730
Allergy, Drug
[description not available]		01.9710
Drug Hypersensitivity
Immunologically mediated adverse reactions to medicinal substances used legally or illegally.		01.9710
Glaucoma
An ocular disease, occurring in many forms, having as its primary characteristics an unstable or a sustained increase in the intraocular pressure which the eye cannot withstand without damage to its structure or impairment of its function. The consequences of the increased pressure may be manifested in a variety of symptoms, depending upon type and severity, such as excavation of the optic disk, hardness of the eyeball, corneal anesthesia, reduced visual acuity, seeing of colored halos around lights, disturbed dark adaptation, visual field defects, and headaches. (Dictionary of Visual Science, 4th ed)		01.9710